Join us for a live satellite symposium on pulmonary arterial hypertension (PAH) treatment. Expert faculty will share insights into disease-modifying therapies (DMTs) and new clinical trial data. Learn how to integrate emerging and existing therapies into a risk-based approach to PAH management. Don’t miss this opportunity to enhance your expertise and take part in discussions that will equip you with actionable insights to improve patient outcomes. FREE CME DINNER SYMPOSIUM Pulmonary Hypertension: Diagnosis, Management, and Updates November 16, 2024 | 6:30 PM - 8:30 PM CST Marriott Marquis Chicago | Great Lakes Ballroom G (Second Floor) 2121 South Prairie Avenue, Chicago, IL Register Today at REACHMD.COM/AHA24 PROVIDED BY: CHAIR Vallerie V. McLaughlin, MD Kim A. Eagle, MD Endowed Professor of Cardiovascular Medicine Director, Pulmonary Hypertension Program University of Michigan Medical School Ann Arbor, MI FACULTY Marc Humbert, MD, PhD Professor of Respiratory Medicine Assistance Publique – Hôpitaux de Paris Université Paris-Saclay Inserm, France Ryan J. Tedford, MD, FACC, FAHA, FHFSA Professor of Medicine/Cardiology Peter C. Gazes Endowed Chair in Heart Failure Medical University of South Carolina Charleston, SC PAID ADVERTISEMENT The symposium will cover: • The role of novel disease-modifying therapies (DMTs) in treating PAH • The impact of current PAH treatments versus novel DMTs • How to identify appropriate patients for DMTs and customize treatment with risk-based assessments Commercial Support: This activity is supported by an independent educational grant from Merck & Co., Inc. This event is not part of the official Scientific Sessions 2024 as planned by the American Heart Association Committee on Scientific Sessions Program.
RkJQdWJsaXNoZXIy MjI2NjI=